ArticleJournal of Alzheimer's disease : JAD2026
Cadmium exposure and incidence of all-cause dementia and Alzheimer's disease in US adults.
Article in Journal of Alzheimer's disease : JAD, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundWhile longitudinal studies aid in understanding and preventing long-latency disorders like dementia, evidence for cadmium's role in these conditions is still limited.ObjectiveWe evaluated the association between cadmium exposure, Alzheimer's disease (AD) and all-cause dementia incidence in US adults.MethodsNational Health and Nutrition Examination Survey (NHANES) III (1988-1994) and continuous NHANES (1999-2016) data were linked with Medicare claims to identify incident AD and dementia cases through 2018. Urinary and/or blood cadmium were measured during NHANES. We used covariate-adjusted, survey-weighted Cox proportional hazard models to evaluate the associations between cadmium exposure biomarkers and AD/dementia over follow-up.ResultsIn NHANES III (N = 6122), mean baseline age was 53.9 years and urinary cadmium was 0.76 µg/L. Over a mean follow-up of 20.4 years, 743 AD and 1508 all-cause dementia cases occurred. Urinary cadmium was not associated with AD (HR: 1.01, 95% CI: 0.9-1.0) nor all-cause dementia incidence (HR: 1.02, 95% CI: 0.96-1.08). In continuous NHANES (urinary cadmium N = 2833; blood cadmium N = 8038), mean baseline age was 64.1 years, urinary cadmium was 0.49 µg/L, and blood cadmium was 0.55 µg/L. Over mean 9.5 years, 587 AD and 1260 all-cause dementia cases occurred. Urinary and blood cadmium showed no associations with AD (HR [95% CI]: 1.09 [0.9, 1.4]; 1.06 [0.9, 1.2]) nor all-cause dementia (HR [95% CI]: 1.07 [0.9, 1.3]; 1.06 [0.95, 1.2]).ConclusionsNo association between cadmium exposure and dementia incidence was observed. Our null findings should be interpreted in the context of potential methodological issues and should be verified by subsequent studies.
Indexed as
Identifiers
42725989What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.